OncoTricks

Myeloma and clots, Oct 9, 2026

A new myeloma: three tests, sent together

If you remember one thingA normal total protein does not rule out myeloma. Anemia, high calcium or kidney failure without a clear cause: send electrophoresis, immunofixation and serum free light chains together.

The clue is on the routine panel

Hemoglobin8.4 g/dL Calcium13.1 mg/dL Creatinine5.8 mg/dL Total protein5.6 g/dL Albumin3.1 g/dL 1 2

An invented example. This patient returns in the next two tabs.

1
Anemia, high calcium and kidney failure together. Think myeloma before the list of separate causes.
2
The total protein is not high. Globulin is 5.6 minus 3.1, so 2.5, which is normal. About 1 myeloma in 5 makes light chains only, with no tall spike.

First-day orders

Protein electrophoresis+Immunofixation+Serum free light chains

In 467 patients with myeloma, electrophoresis plus free light chains found every case the full five-test panel found. Six were found only because free light chains had been added.Mayo Clinic (Katzmann 2009). In another series of 1,027 patients, 20% made light chains only and 3% made no measurable protein.

Also from blood and urine24-hour urine protein with electrophoresis.
Blood count, calcium, creatinine, albumin.
Beta-2 microglobulin and lactate dehydrogenase (LDH), for staging.
Marrow and bonesMarrow aspirate and biopsy, with FISH (chromosome testing) on the plasma cells.
Whole-body low-dose CT in place of the X-ray skeletal survey. PET/CT or MRI are alternatives.

Four emergencies at presentation

Spinal cord compression

New back pain with weakness, numbness or bladder change. MRI of the whole spine the same day, and dexamethasone.

Thick blood (hyperviscosity)

Blurred vision, nosebleeds, confusion. Plasma exchange on symptoms, without waiting for a viscosity result, and before any red cell transfusion.

Severe high calcium

Fluids first. Calcitonin for speed, then zoledronic acid to hold it, or denosumab when the kidney is failing.

Kidney failure

Treatment starts the same day. See the next tab.

Organ damage: C, R, A, B

C

Calcium

Above 11 mg/dL, or more than 1 mg/dL above the laboratory limit.

R

Renal

Creatinine above 2 mg/dL, or clearance under 40 mL/min.

A

Anemia

Hemoglobin under 10 g/dL, or more than 2 g/dL below normal.

B

Bone

One or more holes in bone (lytic lesions): 5 mm or larger on CT or PET/CT, any size on X-ray.

The damage has to come from the plasma cells. Kidney failure from diabetes does not count.

Is it myeloma, or a step before it?

Plasma cells 10% or more in the marrow, or M-protein 3 g/dL or more?M-protein is the single abnormal antibody on electrophoresis. In urine: 500 mg per 24 hours or more.
no
MGUS, if there is no organ damageMonoclonal gammopathy of undetermined significance. Watch.
yes
Any organ damage?The four letters above
yes
MyelomaTreat
no
Any of three markers?Plasma cells 60% or more. Free light chain ratio 100 or more, with the chain the myeloma makes at 100 mg/L or more. More than one MRI lesion of 5 mm or more.
yes
MyelomaTreat before the damage arrives
no
Smoldering myelomaWatch. For high-risk cases, daratumumab was approved in November 2025.

Myeloma needs 10% plasma cells or a biopsy-proven plasmacytoma, plus organ damage or a marker. Organ damage with a small clone: look for amyloidosis, kidney deposits or a plasmacytoma, and repeat the marrow or imaging. A single plasmacytoma without organ damage is a solitary plasmacytoma, not smoldering myeloma.

Sources

Retrieved from PubMed (abstracts and full text) and the criteria pages of the International Myeloma Working Group, read on Oct 15, 2026.

  1. Rajkumar SV, et al. Updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014. doi:10.1016/S1470-2045(14)70442-5
  2. Katzmann JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009. doi:10.1373/clinchem.2009.126664
  3. Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003. doi:10.4065/78.1.21
  4. van Hoeven KH, et al. The anion gap and routine serum protein measurements in monoclonal gammopathies. Clin J Am Soc Nephrol 2011. doi:10.2215/CJN.07380711
  5. Hillengass J, et al. Imaging in monoclonal plasma cell disorders. Lancet Oncol 2019. doi:10.1016/S1470-2045(19)30309-2
  6. Gertz MA. Acute hyperviscosity. Blood 2018. doi:10.1182/blood-2018-06-846816
  7. El-Hajj Fuleihan G, et al. Treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 2023. doi:10.1210/clinem/dgac621
  8. Dimopoulos MA, et al. Daratumumab or active monitoring for high-risk smoldering myeloma. N Engl J Med 2025. doi:10.1056/NEJMoa2409029